Video

Dr. Badani discusses PSMA-targeting agents in prostate cancer

Author(s):

Urology Times staff

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      “There's going to be a whole slew of interesting therapies that are about to emerge for prostate cancer, adds Ketan K. Badani, MD, in this video. Badani is a professor of urology at Icahn School of Medicine at Mount Sinai, vice chairman of urology and robotic operations at Mount Sinai Health System, director of robotic surgery at Mount Sinai West, and the director of the Comprehensive Kidney Cancer Program At Mount Sinai Health System, New York.

      Related Videos
      Kelly Stratton, MD, reacts to FDA approval of Gozellix for prostate cancer imaging
      Kelly Stratton, MD, reacts to FDA approval of Gozellix for prostate cancer imaging
      Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
      PSMA PET and treatment intensification in mHSPC
      Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
      Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
      Amar Kishan, MD, on implications of MIRAGE trial data
      Amar Kishan, MD, on implications of MIRAGE trial data
      Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT
      Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT
      Amar Kishan, MD, outlines the rationale for the MIRAGE trial
      Amar Kishan, MD, outlines the rationale for the MIRAGE trial
      Michael Cookson, MD, on potential future applications of PSMA-PET
      Michael Cookson, MD, on potential future applications of PSMA-PET
      Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template
      Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template
      Michael Cookson, MD, on challenges with PSMA-PET imaging
      Michael Cookson, MD, on challenges with PSMA-PET imaging
      Jeremie Calais, MD, on development of a prostate cancer imaging reporting template
      Jeremie Calais, MD, on development of a prostate cancer imaging reporting template
      Related Content
      Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617
      April 8th 2025

      Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617

      Phillip Kuo, MD, PhD Hannah Clarke
      "For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR.
      Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
      June 22nd 2023

      Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

      Urology Times staff
      "We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
      18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates
      March 31st 2025

      18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates

      Phillip Kuo, MD, PhD
      "I think a take-home message there is that in the prostate/prostate bed, you have to take extra time and caution in reading that region," says Phillip H. Kuo, MD, PhD.
      Study finds geographic disparities in MRI use in prostate cancer
      March 27th 2025

      Study finds geographic disparities in MRI use in prostate cancer

      Hannah Clarke
      The use of pre-diagnostic MRI was 3.8% in 2012, which increased to 32.6% in 2019.
      FDA approves PET imaging product Gozellix for prostate cancer
      March 20th 2025

      FDA approves PET imaging product Gozellix for prostate cancer

      Hannah Clarke
      Gozellix – after radiolabeling with 68Ga – is indicated for PET imaging of PSMA positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and those who have suspected recurrence based on an elevated serum prostate-specific antigen level.
      64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer
      March 6th 2025

      64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer

      Hannah Clarke
      The detection rate ranged from 44% to 58% on day 0 and 58% to 80% on day 1.
      © 2025 MJH Life Sciences

      All rights reserved.